SCHEMBL21957976

SCHEMBL21957976

CC(C)(C)[Si](C)(C)OCc1nccnc1C(=O)O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 1/20 0.33
▸ TACR1 P25103 1/20 0.33
▸ MAPT P10636 5/20 0.33
▸ TSHR P16473 2/20 0.33
▸ CHRM2 P08172 2/20 0.33
▸ CHRM4 P08173 2/20 0.33
▸ CHRM5 P08912 2/20 0.33
▸ CHRM1 P11229 2/20 0.33
▸ CHRM3 P20309 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ KDM4E B2RXH2 6/20 0.32
▸ ALOX15 P16050 2/20 0.32
▸ L3MBTL1 Q9Y468 2/20 0.32
▸ ALDH1A1 P00352 3/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ BLM P54132 1/20 0.32
▸ AGER Q15109 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31245536 1.00 BACE1 (0.33) BACE1TACR1MAPTTSHRCHRM2
SCHEMBL21957858 0.85 L3MBTL1 (0.37) BACE1TACR1MAPTKMT2AKDM4E
SCHEMBL31245546 0.78 KDM4E (0.44) MAPTTSHRCHRM2CHRM4CHRM5
SCHEMBL21957880 0.78 KDM4E (0.44) MAPTTSHRCHRM2CHRM4CHRM5
SCHEMBL29770728 0.78 KDM4E (0.53) BACE1TACR1MAPTTSHRCHRM2
SCHEMBL17986906 0.78 KDM4E (0.53) BACE1TACR1MAPTTSHRCHRM2
SCHEMBL8623554 0.76 CHRM2 (0.45) MAPTTSHRCHRM2CHRM4CHRM5
SCHEMBL30289758 0.76 KMO (0.38) BACE1MAPTTSHRKDM4EALOX15
SCHEMBL16375222 0.76 KMO (0.38) BACE1MAPTTSHRKDM4EALOX15
SCHEMBL31132954 0.76 KDM5A (0.35) BACE1TACR1TSHRCHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260103454-A1 MODULATORS OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS INC (US) 2026-04-16 — — US disclosed
US-20230159507-A1 MODULATORS OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS, INC. 2023-05-25 — — US disclosed
US-20230159507-A1 MODULATORS OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS, INC. 2023-05-25 — — US disclosed
US-20230159507-A1 MODULATORS OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS, INC. 2023-05-25 — — US disclosed
US-11548880-B2 Modulators of hemoglobin GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-01-10 — — US disclosed
EP-4046988-A1 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN Global Blood Therapeutics, Inc. (US) 2022-08-24 — — EP disclosed
EP-4046988-A1 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN Global Blood Therapeutics, Inc. (US) 2022-08-24 — — EP disclosed
EP-3880654-B1 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS INC (US) 2021-12-29 — — EP disclosed
EP-3880654-B1 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS INC (US) 2021-12-29 — — EP disclosed
EP-3880654-A1 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN Global Blood Therapeutics, Inc. (US) 2021-09-22 — — EP disclosed
US-20210047309-A1 MODULATORS OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS, INC. 2021-02-18 — — US disclosed
US-10683285-B2 Modulators of hemoglobin GLOBAL BLOOD THERAPEUTICS, INC. (US) 2020-06-16 — — US disclosed
US-10683285-B2 Modulators of hemoglobin GLOBAL BLOOD THERAPEUTICS, INC. (US) 2020-06-16 — — US disclosed
US-20200157085-A1 MODULATORS OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS, INC. 2020-05-21 — — US disclosed
US-20200157085-A1 MODULATORS OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS, INC. 2020-05-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200157085-A1 MODULATORS OF HEMOGLOBIN HBG1, HBG2, HBB BACE1 4843/4885TACR1 3695/4885MAPT 4092/4885
US-10683285-B2 Modulators of hemoglobin HBG1, HBG2, HBB BACE1 4843/4885TACR1 3695/4885MAPT 4092/4885
US-20210047309-A1 MODULATORS OF HEMOGLOBIN HBG1, HBG2, HBB BACE1 4843/4885TACR1 3695/4885MAPT 4092/4885
US-20230159507-A1 MODULATORS OF HEMOGLOBIN HBG1, HBG2, HBB BACE1 4843/4885TACR1 3695/4885MAPT 4092/4885
US-20260103454-A1 MODULATORS OF HEMOGLOBIN HBZ, HBB, HBG2 BACE1 1693/4885TACR1 958/4885MAPT 3133/4885
US-11548880-B2 Modulators of hemoglobin HBG1, HBG2, HBB BACE1 4843/4885TACR1 3695/4885MAPT 4092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback